chartexchange

AVIR
Atea Pharmaceuticals, Inc. Common Stock
stockNASDAQ

Market OpenNov 17, 2026 10:16:39 AM EST
4.03USD-2.063%(-0.09)20,120
3.4000Bid5.1300Ask1.7300Spread
Loading…
Loading…
324.83M
Healthcare
Biotechnology
HQ
Boston, MA, USA
Previous Close
$4.12
Beta
0.87
52-Week High
$6.45 2026-03-10
52-Week Low
$2.92 2025-11-17
SMA 50
$4.76
SMA 200
$4.95
Avg. Vol 10D
288,501
Avg. Vol 30D
298,525
Avg. Vol 90D
299,348
Relative Vol
0.07
60.63M
0.5100%
1,000,000
566
Mar 4, 2027 (107d)
AVIR Profile

atea pharmaceuticals, inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for severe viral diseases. the company's lead product candidate is at-527, a novel antiviral agent for the treatment of patients infected with severe acute respiratory syndrome coronavirus 2 and is under phase 3 clinical trial. it also develops at-787 which is under phase 2 clinical for the treatment of hepatitis c virus; at-752 which is under phase 2 clinical trial for the treatment of dengue; and at-889, at-934, and other product candidates for the treatment of respiratory syncytial virus are under phase 2 clinical trials. the company was incorporated in 2012 and is based in boston, massachusetts.

AVIR Performance
PeriodPriceDateChangeBeta
1W4.202026-11-10-3.69%1.407
1M4.322026-10-16-6.37%1.496
3M5.222026-08-17-22.51%1.674
6M4.142026-05-18-2.29%1.095
1Y3.022025-11-17+33.94%0.868
2Y3.172024-11-18+27.60%—
5Y8.692021-11-17-53.45%1.023
AVIR Stock Summary

Atea Pharmaceuticals, Inc. Common Stock (NASDAQ:AVIR) stock price today is $4.05, and today's volume is 20,068. AVIR is down 1.820% today. The 30 day average volume is 298,525. AVIR market cap is $324.83M with 80.30M shares outstanding.